Therapeutic Solutions International Awards Distribution of NanoStilbene and Nano Cannabidiol in Mexico to Immun ET Laboratori...
May 06 2019 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions
International Awards Distribution
of NanoStilbene and Nano
Cannabidiol in Mexico to
Immun ET Laboratories,
LLC.
NanoStilbene Shown to
Enhance Anticancer Immunity in Cancer Patients through
Modulation of Inflammatory Mediators
OCEANSIDE, CA -- May
6, 2019 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced
today
a sales
agreement
for the exclusive distribution of NanoStilbene
and
Nano
Cannabidiol throughout Mexico
with Immun
ET.
TSOI recently
announced preliminary data for immune stimulation in advanced
cancer patients with NanoStilbene,
a
nanoemulsion of nanoparticle pterostilbene that is taken
orally. Daily treatment with
NanoStilbene caused a reduction in serum levels of inflammatory
markers TNF-alpha, IL-6, and CRP. Assessment of peripheral blood
mononuclear cell ability to generate IFN-gamma subsequent to
stimulation with anti-CD3 and anti-CD28 was increased.
Additionally, NK cytotoxicity was augmented.
These results suggest
that NanoStilbene may be a useful adjuvant to immunotherapy of
cancer rescuing T cell and NK cell activities. Augmentation of NK
cell function may stimulate efficacy of approved therapies that
depend on an active NK compartment such as Herceptin, Rituximab,
and Cetuximab.
The Nano Cannabidiol
product we have produced is built upon the same nano particle
platform as NanoStilbene. This
provides for
good
protection and oral delivery system, the
nanoemulsion for
cannabidiol isolate uses the same
low-energy
emulsification method as
NanoStilbene. Nanoemulsions are
non-equilibrium systems and possess kinetic stability in a long
period with a remarkable small
droplet size (below 200 nm).
The cannabidiol
isolate (which contains
zero
THC, and
zero
Terpenes) we
place
in the
nanodroplet is free
from air, light, and hard environment
and
contains 200mg of >99% pure isolate per milliliter of
liquid.
Typical
clinical doses of cannabidiol are in the range of 15-20mg daily. 2
drops of our Nano Cannabidiol provides
20mg.
"We
are
pleased to make this announcement today for Immun ET
Laboratories to have
exclusive
distribution rights
for NanoStilbene and
Nano
Cannabidiol throughout all of
Mexico" said Tim G Dixon
CEO & President of Therapeutic Solutions International,
Inc. "Having worked closely
with the principal of
Immun ET, Dr.
Javier
Lopez,
for many
years in advanced cancer studies where in 2015 we
conducted our 10 patient StemVacs immunotherapy clinical
trial, we are excited to
continue our long-standing relationship further solidified by
this award
announced
today."
"Immun ET is very
excited to offer both of these nano particle compounds
from TSOI
to our customers in both their
original form and in various blends together we are
calling NanoVita
and
NanoVita
Plus.
Having the privilege to observe all of the work in developing
NanoStilbene, essentially from
bench to bedside, including
a
pharmacokinetic study and
a
clinical trial of advanced cancer patients, we have
eagerly
awaited this day to be able to provide this patented immune
adjuvant to cancer patients in Mexico" said Dr.
Javier
Lopez,
Chief Executive
Officer of
Immun ET
Laboratories. "And in addition,
having the ability to distribute exclusively
their
Nano Cannabidiol in Mexico
as
well, gives us two very
potent and highly concentrated formulations to meet a variety of
clinical needs" added Dr. Lopez.
About Therapeutic
Solutions International, Inc.
Therapeutic Solutions International is focused on
immune modulation for the treatment of several specific diseases.
Immune modulation refers to the ability to upregulate (make more
active) or downregulate (make less active) one's immune system. The
Company's corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on NanoStilbene
visit www.nanostilbene.com.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
About
Immun ET Laboratories,
LLC.
Immun
ET focuses on the
development and commercialization of immunological and regenerative
therapies to cover medical needs.
Safe Harbor
Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
Contact
Information:
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024